3results about How to "Meet activity" patented technology

The utility model discloses an assembled cat rack, including two bowl cat nest and support plate subassembly, support plate subassembly includes first support plate subassembly and second support plate subassembly, both cross -set, first support plate subassembly includes two symmetrical support plate no.

The utility model provides a kind of connecting structure of quick faucet, including faucet body, its lower portion water inlet end is equipped with hose connection, internal thread;Connecting structure, it includes connecting flange, flange gland, flange gland has internal thread, inner ring, connecting flange has outer thread, outer ring, both press tightly and cooperate and outer ring is limited in inner ring, connecting flange is threadedly cooperated with faucet body;Fixed structure, it includes upper connecting plate, lower connecting plate, connecting bolt, upper connecting plate is threadedly cooperated with flange gland, upper and lower connecting plate are connected by connecting bolt, and sealing gasket is arranged between upper connecting plate and connecting flange, table top.This structure realizes quick installation, stable connection and good sealing, is convenient to maintain, improves faucet installation and use experience, satisfies efficient and convenient installation demand.

This application discloses a drug design method, apparatus, device, and medium based on an RNA basic model and thermodynamically guided discrete diffusion, relating to the field of drug design technology. The method includes: acquiring the original RNA drug sequence and inputting it into an RNA basic model to extract RNA feature information; performing inverse denoising on the noise sequence at the current time step using a pre-trained discrete diffusion model and based on the RNA feature information to generate candidate chemically modified sequences; calculating the drug-likeness index of the candidate chemically modified sequences; determining the energy classifier gradient information at the current time step based on the drug-likeness index; using the energy classifier gradient information to correct the candidate chemically modified sequences to obtain the target chemically modified sequence at the current time step; using this target chemically modified sequence as the noise sequence for the next time step for iterative inverse denoising; and outputting the drug design result. This ensures that the corrected chemically modified sequence simultaneously satisfies stability, activity, and safety.